Fierce Biotech August 7, 2024
Charles River Laboratories has reported its second-quarter earnings, with the CRO seeing revenue decline from $1.06 billion in the second quarter of last year to $1.03 billion. Demand for the company’s services is likely to continue its downward trajectory through the rest of the year, according to an Aug. 7 release.
After excluding the effect of foreign currency translation, an acquisition and a divestment, revenues dropped organically by 3.2% year over year. The decline was driven by revenue drops in the Discovery and Safety Assessment (DSA) and Research Models and Services segments of the company.
“Our financial performance through the first half of this year has been largely in line with our initial outlook,” Charles River’s CEO, chair, and president...
Today's Sponsors
Today's Sponsor